Miller Anestesia

Tucek S, Michal P, Vlachova V: Modelling the consequen-

ces of receptor–G-protein promiscuity. Trends Phar-

macol Sci 23:171–176, 2002.

Vaughan M: Signaling by heterotrimeric G proteins mini-

review series. J Biol Chem 273:17297, 1998.

Watson J, Gilman M, Witkowski J, et al: Recombinant

DNA, 3rd ed. New York, Scientific American,

2007.

Weinshilboum R: Inheritance and drug response. N Engl

J Med 348:529–537, 2003.

Wilkinson GR: Pharmacokinetics: The dynamics of drug

absorption,distribution,and elimination.InHardman

JG, Limbird LE (eds): The Pharmacological Basis of

Therapeutics, 10th ed. New York, McGraw-Hill,

2002.

Bibliografía

1. Krejcie TC, Avram MJ, Gentry WB, et al: A recircula-

tory model of the pulmonary uptake and pharmaco-

kinetics of lidocaine based on analysis of arterial and

mixed venous data from dogs. J Pharmacokinet

Biopharm 25:169–190, 1997.

2. Shafer S: Principles of pharmacokinetics and pharma-

codynamics.

Longnecker DE, Tinker JH, Morgan

GE (eds): Principles and Practice of Anesthesiology,

2nd ed. St Louis, Mosby–Year Book, 1997.

3. Wagner JG: Pharmacokinetics for the Pharmaceutical

Scientist. Lancaster, PA, Technomic Publishing, 1993.

4. Wilkinson GR, Shand DG: Commentary: A physiolo-

gical approach to hepatic drug clearance. Clin Phar-

macol Ther 18:377–390, 1975.

5. Cockcroft DW, Gault MH: Prediction of creatinine

clearance from serum creatinine. Nephron 16:31–41,

1976.

6. Ebling WF, Wada DR, Stanski DR: From piecewise to

full physiologic pharmacokinetic modeling: Applied

to thiopental disposition in the rat. J Pharmacokinet

Biopharm 22:259–292, 1994.

7. Bjorkman S, Wada DR, Stanski DR: Application of

physiologic models to predict the influence of changes

in body composition and blood flows on the pharma-

cokinetics of fentanyl and alfentanil in patients.Anes-

thesiology 88:657–667, 1998.

8. Youngs EJ, Shafer SL: Basic pharmacokinetic and

pharmacodynamic principles.

White PF (ed): Text-

book of Intravenous Anesthesia. Baltimore, Williams

& Wilkins, 1997, p 10.

9. Scott JC, Ponganis KV, Stanski DR: EEG quantitation

of narcotic effect: The comparative pharmacodyna-

mics of fentanyl and alfentanil. Anesthesiology

62:234–241, 1985.

10. Mandema JW, Kuck MT, Danhof M: Differences in

intrinsic efficacy of benzodiazepines are reflected in

their concentration-EEG effect relationship. Br J

Pharmacol 105:164–170, 1992.

11. Milano CA, Allen LF, Rockman HA, et al: Enhanced

myocardial function in transgenic mice overexpres-

sing the beta 2-adrenergic receptor. Science 264:582–

586, 1994.

12. Engelhardt S, Grimmer Y, Fan G-H, Lohse MJ: Cons-

titutive activity of the human

-adrenergic receptor

-receptor transgenic mice. Mol Pharmacol

60:712–717, 2001.

13. Liu X,Callaerts-Vegh Z,Evans KLJ,Bond RA: Chronic

infusion of

-adrenoceptor antagonist and inverse

agonists decreases elevated protein kinase A activity

in transgenic mice with cardiac-specific overexpres-

sion of human

ARs. J Cardiovasc Pharmacol

40:448–455, 2002.

14. Stapelfeldt WH: The autonomic nervous system.

Schwinn DA (ed): Scientific Principles of Anesthesia

vol 2. Philadelphia, Current Medicine, 1998.

15. Berkowitz DE: Cellular signal transduction.

Schwinn DA (ed). Scientific Principles of Anes-

thesia vol 2. Philadelphia, Current Medicine,

1998.

16. Firestone L, Quinlan J, Gyulai F: Mechanisms of anes-

thetic action.

. Schwinn DA (ed): Scientific Princi-

ples of Anesthesia vol 2. Philadelphia, Current

Medicine, 1998.

17. Krasowski MD, Harrison NL: General anaesthetic

actions on ligand-gated ion channels. Cell Mol Life

Sci 55:1278–1303, 1999.

18. Jurd R, Arras M, Lambert S, et al: General anesthetic

actions in vivo strongly attenuated by a point muta-

tion in the GABA(A) receptor beta3 subunit. FASEB

J 17:250–252, 2003.

19. McEwan AI, Smith C, Dyar O, et al: Isoflurane

minimum alveolar concentration reduction by fen-

tanyl. Anesthesiology 78:864–869, 1993.

20. Vuyk J, Lim T, Engbers FH, et al: The pharmacodyna-

mic interaction of propofol and alfentanil during

lower abdominal surgery in women. Anesthesiology

83:8–22, 1995.

21. Hendrickx JFA, Eger EI, Sonner JM, Shafer SL: Is

synergy the rule? A review of anesthetic interactions

producing hypnosis and immobility. Anesth Analg

107:494–506, 2008.

22. Minto CF, Schnider TW, Short TG, et al: Response

surface model for anesthetic drug interactions. Anes-

thesiology 92:1603–1616, 2000.

23. Lamba JK, Lin YS, Thummel K, et al: Common allelic

variants of cytochrome P4503A4 and their prevalence

in different populations. Pharmacogenetics 12:121–

132, 2002.

24. Dai D, Tang J, Rose R, et al: Identification of variants

of CYP3A4 and characterization of their abilities to

metabolize testosterone and chlorpyrifos. J Pharma-

col Exp Ther 299:825–831, 2001.

25. Blaisdell J, Mohrenweiser H, Jackson J, et al: Identifi-

cation and functional characterization of new poten-

tially defective alleles of human CYP2C19.

Pharmacogenetics 12:703–711, 2002.

26. Poulsen L, Brosen K,Arendt-Nielsen L, et al: Codeine

and morphine in extensive and poor metabolizers of

sparteine: Pharmacokinetics, analgesic effect and side

effects. Eur J Clin Pharmacol 51:289–295, 1996.

27. Johnson JA, Terra SG:

-Adrenergic receptor

polymorphisms: Cardiovascular disease associations

and pharmacogenetics. Pharm Res 19:1779–1787,

2002.

28. Large V, Hellstrom L, Reynisdottir S, et al: Human

beta-2 adrenoceptor gene polymorphisms are highly

frequent in obesity and associate with altered adipo-

cyte beta-2 adrenoceptor function. J Clin Invest

100:3005–3013, 1997.

29. Dishy V, Sofowora GG, Xie HG, et al: The effect of

common polymorphisms of the beta2-adrenergic

receptor on agonist-mediated vascular desensitiza-

tion. N Engl J Med 345:1020–1035, 2002.

30. Israel E: Genetics and the variability of treatment res-

ponse in asthma. J Allergy Clin Immunol 115:S532–

S538, 2005.

31. Homer TD, Stanski DR: The effect of increasing age

on thiopental disposition and anesthetic requirement.

Anesthesiology 62:714–724, 1985.

32. Bell GD, Spickett GP, Reeve PA, et al: Intravenous

midazolam for upper gastrointestinal endoscopy: A

study of 800 consecutive cases relating dose to age

and sex of patient. Br J Clin Pharmacol 23:241–243,

1987.

33. Scott JC, Stanski DR: Decreased fentanyl and alfenta-

nil dose requirements with age.A simultaneous phar-

macokinetic and pharmacodynamic evaluation. J

Pharmacol Exp Ther 240:159–166, 1987.

34. Minto CF, Schnider TW, Egan TD, et al: Influence of

age and gender on the pharmacokinetics and phar-

macodynamics of remifentanil. I. Model develop-

ment. Anesthesiology 86:10–23, 1997.

35. Schnider TW, Minto CF, Shafer SL, et al: The influence

of age on propofol pharmacodynamics. Anesthesio-

logy 90:1502–1516, 1999.

36. Bailey DG, Malcolm J, Arnold O, Spence JD: Grape-

fruit juice–drug interactions. Br J Clin Pharmacol

46:101–110, 1998.

Principios básicos de farmacología

279

Sección II

Farmacología y anestesia